SecBot SecBot
SECBOTREPLAY Home › Report › IVVD

IVVD · Invivyd (IVVD) announced receipt of a 12-month advanced notice of EUA…

Invivyd, Inc. · 8-K filed Jul 6, 2026 at 07:11 ET

At the news

BEARISHIMPACT 6/10

8-K filed Jul 6, 2026 at 07:11 ET

Invivyd (IVVD) announced receipt of a 12-month advanced notice of EUA termination for its only authorized product, PEMGARDA (pemivibart), following HHS termination of the COVID-19 EUA declaration effective June 29, 2027. The company intends to pursue a BLA for full FDA approval and is in active dialogue with the FDA. The termination removes the product's current authorization but provides a transition period; the outcome of the BLA path is uncertain.

  • FDA sent Notice of Termination for PEMGARDA EUA, effective June 29, 2027 (12-month transition period).
  • HHS announced termination of the COVID-19 EUA declaration on June 30, 2026, effective June 29, 2027.
  • Invivyd intends to submit a Biologics License Application (BLA) for full approval of PEMGARDA.
  • PEMGARDA is Invivyd's only authorized product, used for pre-exposure prophylaxis of COVID-19 in immunocompromised individuals.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access